Nutriband (US:NTRB)2025-12-10 22:41Revenue Performance - Revenue for the three months ended October 31, 2025, was $346,058, a decrease from $645,796 in the same period of 2024, representing a decline of approximately 46.4%[11] - For the nine months ended October 31, 2025, revenue increased to $1,635,942, compared to $1,497,158 for the same period in 2024, reflecting a growth of about 9.3%[11] - Total revenue for the nine months ended October 31, 2025, was $1,635,942, an increase from $1,497,158 for the same period in 2024, representing an 9.3% growth[40] - Revenue from the sale of goods in the three months ended October 31, 2025, was $346,058, compared to $645,796 in the same period of 2024, indicating a decline of 46.4%[40] Net Loss and Expenses - The net loss for the three months ended October 31, 2025, was $3,872,367, compared to a net loss of $1,362,637 for the same period in 2024, representing an increase in loss of about 184.5%[11] - The company reported a net loss available to common stockholders of $29,075,739 for the nine months ended October 31, 2025, compared to $4,966,179 for the same period in 2024, indicating a significant increase in loss[11] - For the nine months ended October 31, 2025, the company reported a net loss of $7,261,573, compared to a net loss of $4,966,179 for the same period in 2024[18] - Selling, general and administrative expenses for the three months ended October 31, 2025, were $3,491,728, significantly higher than $737,102 in the same period of 2024, an increase of about 373.5%[11] - Selling, general and administrative expenses for the nine months ending October 31, 2025, were $6,071,320, a significant increase from $2,554,155 in the same period of 2024, primarily due to higher equity-based expenses[126] Research and Development - Research and development expenses for the nine months ended October 31, 2025, were $1,703,093, down from $2,629,278 in the same period of 2024, a decrease of approximately 35.2%[11] - Research and development expenses for the Aversa Fentanyl product were $457,113 for the three months ending October 31, 2025, down from $880,768 in 2024, mainly due to reduced labor costs[122] - Research and development expenses for the Aversa Fentanyl product amounted to $1,703,093 for the nine months ending October 31, 2025, down from $2,629,278 in the same period of 2024, mainly due to reduced labor costs[127] Assets and Liabilities - Total current assets as of October 31, 2025, were $5,815,064, up from $4,794,265 as of January 31, 2025, indicating an increase of approximately 21.3%[9] - Total liabilities as of October 31, 2025, were $870,208, a decrease from $1,041,050 as of January 31, 2025, reflecting a reduction of approximately 16.4%[9] - Cash and cash equivalents increased to $5,312,177 as of October 31, 2025, from $4,311,719 as of January 31, 2025, representing a growth of approximately 23.2%[9] - As of October 31, 2025, the company had cash and cash equivalents of $5,312,177 and working capital of $5,042,529[29] Financing and Capital Structure - The company received proceeds of $5,305,503 from the exercise of warrants during the nine months ended October 31, 2025[29] - The company entered into a three-year $5,000,000 Credit Line Note facility with a related party to fund research and development of its Aversa product[29] - The Company entered an amended Credit Line Note agreement for an increased $5,000,000 credit line facility, with outstanding advances bearing interest at 7% per annum[65] - The Company completed an $8,400,000 equity financing with European investors on April 19, 2024, which included related parties investing a total of $7,120,000[74] Operational Insights - The company generated operating losses since inception and has relied on sales of securities and debt issuance to support cash flow from operations[29] - The company has improved operations and believes it can fund its operations for one year from the date of the filing of the financial statements[30] - The company has conducted product development programs, including preclinical and clinical trials, to receive FDA approval for its pharmaceutical products[22] - The company is currently involved in a lawsuit seeking over $500,000 in damages, while also pursuing counterclaims for $1,000,000 against the plaintiffs[101][102] Market and Growth Outlook - The company reported a significant increase in revenue, achieving $500 million in Q3 2025, representing a 25% year-over-year growth[161] - User data showed a total of 2 million active users, up from 1.5 million in the previous quarter, indicating a 33% increase[161] - The company provided an optimistic outlook for Q4 2025, projecting revenue to reach between $550 million and $600 million, which would mark a 10-20% growth compared to Q3 2025[161] - New product launches are expected to contribute an additional $50 million in revenue in the next quarter, driven by strong pre-orders[161] - The company is investing $20 million in R&D for new technologies aimed at enhancing user experience and product efficiency[161] - Market expansion efforts have led to entry into three new countries, with an anticipated revenue contribution of $30 million in the next fiscal year[161] - The company is exploring potential acquisitions to bolster its market position, with a budget of $100 million allocated for this purpose[161] - A new marketing strategy has been implemented, expected to increase brand awareness and drive sales by 15% in the upcoming quarter[161] - The company reported a gross margin of 60%, maintaining strong profitability despite increased operational costs[161] - Customer satisfaction ratings improved to 90%, reflecting the effectiveness of recent service enhancements[161]